One of the US FDA's newest weapons to help spur antimicrobial development may not be as vital as initially thought. However, industry still needs incentives and now the agency is moving into the reimbursement area to fight against antimicrobial resistance.
The Limited Population Antibacterial Drug (LPAD) pathway allows antibiotics to be approved and labeled for small populations with unmet needs. The program is intended to allow smaller clinical trials and...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?